Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27501223 | 0.89 | NPC1 (0.43) | NPC1RAB9AMEN1KMT2AESR1 | |
| SCHEMBL27449625 | 0.84 | TSHR (0.50) | NPC1TSHRLMNAMAPTHPGD | |
| SCHEMBL27519801 | 0.83 | MEN1 (0.48) | NPC1RAB9AMEN1KMT2AESR1 | |
| SCHEMBL777261 | 0.82 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2AESR1 | |
| SCHEMBL29436920 | 0.82 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2AESR1 | |
| SCHEMBL127127 | 0.82 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2AESR1 | |
| SCHEMBL248052 | 0.80 | KMT2A (0.53) | NPC1RAB9AMEN1KMT2AESR1 | |
| SCHEMBL101601 | 0.80 | TSHR (0.63) | NPC1RAB9AKMT2ATSHRLMNA | |
| SCHEMBL29702037 | 0.80 | TSHR (0.63) | NPC1RAB9AKMT2ATSHRLMNA | |
| SCHEMBL1851122 | 0.78 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112625000-B | Synthesis method of N-alkane-1, 2-benzisothiazolin-3-one | 安徽屹墩科技股份有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-101679191-B | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI AVENTIS SPA | 2014-03-12 | — | — | CN | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| EP-0695184-B1 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5863950-A | AMIDES OR THIO AMIDE COMPOUNDS WITH HYDROXY OR ETHER GROUPS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5714518-A | HIV protease inhibitors and methods of making the same | AGOURON PHARMACEUTICALS (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0695184-A4 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0695184-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994015906-A1 | HIV PROTEASE INHIBITORS AND THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015608-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | F12, F2, PIGS | NPC1 2404/4885RAB9A 1961/4885MEN1 431/4885 |
| US-20100004229-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | NPC1 1004/4885RAB9A 1952/4885MEN1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.